API | galidesivir

galidesivir Report issue

Small molecule Experimental

AACT DrugBank MeSH PubChem

Active Ingredient History

NOW

Galidesivir is an antiviral drug, an adenosine analog. It was developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease, as well as Zika virus. Currently, galidesivir is under phase 1 human trial in Brazil for coronavirus. ^Wikipedia

Chemistry

SMILES: Nc1ncnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12
InChIKey: AMFDITJFBUXZQN-KUBHLMPHSA-N
Mol. Mass: 265.27
ALogP: -1.73 Partition coefficient
ChEMBL Molecule:
galidesivir

More Chemistry

Pharmacology

Mechanisms of Action:
- Genome polyprotein (Yellow fever virus (strain 17D vaccine) (YFV)) ^UniProt
- Genome polyprotein (Zika virus) ^UniProt
- Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2) ^UniProt
- RNA-directed RNA polymerase L (Lake Victoria marburgvirus (strain Musoke-80) (MARV) (Marburg virus (strainKenya/Musoke/1980))) ^UniProt
- RNA-directed RNA polymerase L (Zaire ebolavirus (strain Mayinga-76) (ZEBOV) (Zaire Ebola virus)) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Yes

2-(4-amino-5h-pyrrolo(3,2-d)pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol | bcx4430 | galidesivir

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

COVID-19 (Phase 1)

Filoviridae Infections (Phase 1)

Hemorrhagic Fever, Ebola (Phase 1)

Marburg Virus Disease (Phase 1)

Yellow Fever (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 3
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue